Bremelanotide

Melanocortin Receptor Agonist — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Bremelanotide is an ofp drug in the Melanocortin Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Melanocortin Receptor Agonists. DrugCentral lists 5 molecular targets, including MC1R, MC3R and MC4R. Recorded indications include Lack or loss of sexual desire.

• Approval status: ofp (first approved 2019 by the FDA).
• Drug class: Melanocortin Receptor Agonist.
• Mechanism of action: Melanocortin Receptor Agonists.
• Molecular targets: MC1R, MC3R, MC4R and MC5R (5 listed in DrugCentral).
• Indications: Lack or loss of sexual desire.
• ATC code: G02CX05 (Other gynecologicals).
• Molecular formula: C50H68N14O10; molecular weight 1025.18 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Lack or loss of sexual desire

Contraindications (2)

• Disorder of cardiovascular system
• Hypertensive disorder

Mechanism & targets

• Mechanism of action (MoA): Melanocortin Receptor Agonists
• Established pharmacologic class: Melanocortin Receptor Agonist

Molecular targets (5)

Target	Gene	Action	Activity
Melanocyte-stimulating hormone receptor	MC1R	agonist	EC50 10.02
Melanocortin receptor 3	MC3R	agonist	EC50 8.62
Melanocortin receptor 4	MC4R	agonist	Kd 8.00
Melanocortin receptor 5	MC5R	agonist	Ki 7.77
Adrenocorticotropic hormone receptor	MC2R	agonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2019-06-21	FDA	—	AMAG PHARMS INC

ATC classification

ATC code	Therapeutic hierarchy
G02CX05	GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › OTHER GYNECOLOGICALS › Other gynecologicals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Nausea	130.0

Chemical structure

• Molecular formula: C₅₀H₆₈N₁₄O₁₀
• Molecular weight: 1025.18 g/mol
• CAS number: 189691-06-3
• InChIKey: FFHBJDQSGDNCIV-MFVUMRCOSA-N
• PubChem CID: 9941379

CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bremelanotide used for?

DrugCentral lists the following indications for Bremelanotide: Lack or loss of sexual desire.

How does Bremelanotide work?

Bremelanotide is classified as Melanocortin Receptor Agonists; its molecular targets in DrugCentral include MC1R (agonist), MC3R (agonist), MC4R (agonist) and MC5R (agonist).

When was Bremelanotide first approved?

Bremelanotide was first approved by the FDA in 2019.

What drug class does Bremelanotide belong to?

Bremelanotide is in the Melanocortin Receptor Agonist class.

What is the chemical formula of Bremelanotide?

Bremelanotide has the molecular formula C50H68N14O10 and a molecular weight of 1025.18 g/mol.

Sources

• DrugCentral drug card 5329 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2070241 — compound record and bioactivity
• PubChem CID 9941379 — chemical identifiers
• DrugBank DB11653 — drug record
• FDA UNII 6Y24O4F92S — substance identity
• DailyMed: FDA labels for Bremelanotide — current prescribing information (label search)
• UniProt Q01726 (MC1R) — target protein
• UniProt P41968 (MC3R) — target protein
• UniProt P32245 (MC4R) — target protein
• UniProt P33032 (MC5R) — target protein
• UniProt Q01718 (MC2R) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.